Nachrichten zur Quest Diagnostics Aktie

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.…

Minimale Kursveränderung bei Quest Diagnostics-Aktie (120,7245 €)

CODE Das Wertpapier notiert aktuell bei 128,30 US-Dollar. Kaum auffällig ist derzeit an der Börse der Kurs von Quest Diagnostics.…

Quest Diagnostics (DGX) to Post Q1 Earnings: Whats in Store?

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics (DGX) base business performance in the first quarter…

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal…

Analyst Report: Quest Diagnostics, Inc.

…

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.…

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.…

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.…

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Strength of the base business bodes well for Quest Diagnostics (DGX).…

Earnings call: Quest Diagnostics sees robust growth and AI investment By Investing.com

Earnings call: Quest Diagnostics sees robust growth and AI investment…

Quest Diagnostics-Aktie heute am Aktienmarkt kaum gefragt: Kurs fällt (116,0444 €)

Im Minus liegt derzeit die Aktie von Quest Diagnostics . Das Papier kostete zuletzt 126,16 US-Dollar. Im US-amerikanischen Wertpapierhandel hat…

Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript

…

Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do…

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.…

Quest Diagnostics (DGX) Advances in Cancer Research With New Deal

Quest Diagnostics (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.…

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide…

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.…

Quest Diagnostics (DGX) to Post Q4 Earnings: Whats in Store?

Quest Diagnostics (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.…

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

Quest Diagnostics (DGX) new partnership is likely to leverage its oncology expertise and national scale.…

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.…

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.…

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.…

Quest Diagnostics (DGX) Haystack Oncology Inks New Deal

Quest Diagnostics (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.…

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.…

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.…

Quest Diagnostics (DGX) New Pact to Scale Precision Medicine

Quest Diagnostics (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Sciphers PrismRA test through a new collaboration.…

Quest Diagnostics (DGX) New Pact to Advance Cancer Screening

Quest Diagnostics (DGX) latest partnership will increase the likelihood that Americans will eventually have an easy, reliable and accessible way…

Quest Diagnostics wird eine unveränderte Dividende auszahlen

Der amerikanische Medizintechniker Quest Diagnostics Inc. (ISIN: US74834L1008, NYSE: DGX) zahlt am 31. Januar 2024 eine vierteljährliche Dividende in Höhe…

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostics laboratory testing with the launch of…

Analyst Report: Quest Diagnostics, Inc.

…

Asia Cervical Cancer Screening Markets, 2023-2028 with AstraZeneca, Hologic, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health Dominating

Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Asia Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends,…

dpa-AFX ProFeed